Ftse Mib
36.505,97
-0,58%
DAX
21.585,93
0,35%
S&P 500
6.057,68
0,33%
NASDAQ
19.650,32
-0,02%
Bitcoin
97.646,36
-0,22%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Mangoceuticals Inc (MGRX) Mangoceuticals Inc (MGRX) Notizie

Mangoceuticals Inc

MGRX
3,19
0,01 (0,31%)
Ultimo aggiornamento: 21:03:56
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
03/2/202514:30GLOBEMangoceuticals, Inc. Executes Exclusive Distribution..
31/1/202523:25EDGAR2Form 8-K - Current report
22/1/202523:28EDGAR2Form SCHEDULE 13G - Statement of Beneficial Ownership by..
21/1/202522:30EDGAR2Form 8-K - Current report
15/1/202522:30EDGAR2Form 8-K - Current report
08/1/202522:30EDGAR2Form 8-K - Current report
26/12/202422:30EDGAR2Form 8-K - Current report
19/12/202423:33GLOBEMangoceuticals, Inc. Completes Acquisition of Mushroom-Based..
19/12/202423:30EDGAR2Form 8-K - Current report
06/12/202423:15EDGAR2Form 8-K - Current report
04/12/202413:00GLOBEMangoceuticals, Inc. Initiates Investigation into Potential..
14/11/202422:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/11/202423:04EDGAR2Form 8-K - Current report
31/10/202413:00EDGAR2Form 8-K - Current report
31/10/202413:00GLOBEMangoceuticals, Inc. Regains Full Compliance with Nasdaq..
25/10/202423:00EDGAR2Form 8-K - Current report
22/10/202414:00EDGAR2Form 8-K - Current report
22/10/202414:00GLOBEMangoRx Announces Formation of Strategy and Alternatives..
21/10/202423:10EDGAR2Form 8-K - Current report
21/10/202423:10GLOBEMangoRx Responds to and Refutes Recent Claims Made by Eli..
11/10/202423:15GLOBEMANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK..
03/10/202414:30GLOBEMangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist..
01/10/202419:05APSHealthcare Shares Rise Following Product Availability..
01/10/202413:30GLOBEMangoRx Addresses $49.3 Billion Global GLP-1 Market With..
15/8/202415:25GLOBEMangoRx Reports 1,685% Increase in Shareholders’ Equity From..
13/8/202422:00GLOBEMangoRx Receives Certificate of Grant in India for its..
09/8/202414:15GLOBEMangoRx Completes Migration to DEA-Approved Telemedicine..
24/7/202414:15GLOBEMangoRx Initiates Efficacy Studies on its Patented..
18/7/202422:05GLOBEMangoceuticals CEO Jacob Cohen Featured on Benzinga..
16/7/202414:20GLOBEMangoRx Secures DEA Approval for Proprietary HIPAA-Compliant..
12/7/202419:30GLOBEMangoRx Appoints Dr. Douglas Christianson, N.D. as Director..
11/7/202414:15GLOBEMangoRx Announces Strategic Partnership for Expansion into..
18/6/202420:57EDGAR2Form 144 - Report of proposed sale of securities
10/6/202419:28EDGAR2Form 144 - Report of proposed sale of securities
06/6/202414:30GLOBEMangoRx Receives Notice of Acceptance for Patent Application..
05/6/202423:15EDGAR2Form 8-K - Current report
05/6/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202423:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/6/202422:00GLOBEMangoRx Receives Patent Notice of Allowance in Japan for..
04/6/202414:00GLOBEMangoRx to Introduce “MOJO” Pharmaceutical Compounded..
28/5/202414:30GLOBEMangoceuticals, Inc. Announces Completion of First Batch of..
23/5/202414:30GLOBEMangoRx Engages Renown International Digital and Performance..
21/5/202414:30GLOBEMangoRx to Introduce Oral Semaglutide and Tirzepatide in..
16/5/202422:40GLOBEMangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by..
16/5/202415:19EDGAR2Form DEF 14A - Other definitive proxy statements
15/5/202422:52EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/5/202415:00EDGAR2Form S-8 - Securities to be offered to employees in employee..
06/5/202423:32EDGAR2Form S-1/A - General form for registration of securities..
06/5/202422:43EDGAR2Form PRE 14A - Other preliminary proxy statements
02/5/202414:00GLOBEMangoceuticals Granted 180-Day Extension to Meet Nasdaq..
Apertura: 3,25 Min: 3,15 Max: 3,25
Chiusura: 3,18

La tua Cronologia

NASDAQ
MGRX
Mangoceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci